Cost-utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran

References

• Ferlay J, Ervik M, Lam F, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Int Agency Res Cancer. accessed [2021 Apr 12]. 2020;126(11):2666–2678. Available from. https://gco.iarc.fr/today
   Google Scholar
• Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer.Sunlight, vitamin D and skin cancer. 2014;120–140.
   Google Scholar
• Matthews N Natalie H. Epidemiology of melanoma. Exon Publications; 2017. p. 3–22.
   Google Scholar
• Eide MJ, Krajenta R, Johnson D, et al. Identification of patients with nonmelanoma skin cancer using health maintenance organization claims data. Am J Epidemiol. 2010;171(1):123–128. doi: 10.1093/aje/kwp352
   PubMed Web of Science ®Google Scholar
• NCI. Surveillance, Epidemiology, and end results (SEER) program cancer Statistics review, 1975–2013: National cancer Institute; [ Available from: http://seer.cancer.gov/csr/1975_2013/.
   Google Scholar
• Califano J, Nance M. Malignant Melanoma. Facial Plast Surg Clin North Am. 2009;17(3):337–348. doi: 10.1016/j.fsc.2009.05.002
   PubMedGoogle Scholar
• Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther. 2010;10(11):1811–1823. doi: 10.1586/era.10.170
   PubMed Web of Science ®Google Scholar
• Filippi AR, Fava P, Badellino S, et al. Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiother Oncol. 2016;120(1):1–12. doi: 10.1016/j.radonc.2016.06.003
   PubMed Web of Science ®Google Scholar
• Goodson AG, Grossman D. Strategies for early melanoma detection: approaches to the patient with nevi. J Am Acad Dermatol. 2009;60(5):719–735. doi: 10.1016/j.jaad.2008.10.065
   PubMed Web of Science ®Google Scholar
• Wilson MA, Schuchter LM. Chemotherapy for Melanoma. In: Kaufman H, Mehnert J, editor. Melanoma. Springer, Cham: Cancer Treatment and Research. 2016;209–229. doi: 10.1007/978-3-319-22539-5_8
   Google Scholar
• McArthur GA, Ribas A. Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol. 2013;31(4):499–506. doi: 10.1200/JCO.2012.45.5568
   PubMed Web of Science ®Google Scholar
• Franken MG, Leeneman B, Gheorghe M, et al. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. Eur J Cancer. 2019;123:58–71. doi: 10.1016/j.ejca.2019.08.032
   PubMed Web of Science ®Google Scholar
• Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J National Compr Cancer Network. 2016;14(4):450–473. doi: 10.6004/jnccn.2016.0051
   PubMed Web of Science ®Google Scholar
• CAN) TACSCANA. The costs of cancer: 2020 edition. 2020 Available at: https://www.fightcancer.org/sites/default/files/National%20Documents/Costs-of-Cancer-2020-10222020.pdf.
   Google Scholar
• Vasekar MK, Agbese E, Leslie D. The value of immunotherapy: comparison of annual cost per patient receiving immunotherapy versus chemotherapy in patients with non-small cell lung cancer. Journal of Clinical Oncology. 2020;38(15_suppl):e19364–e19364.
   Google Scholar
• Goldstein DA, Clark J, Tu Y, et al. A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget. 2017;8(42):71548. doi: 10.18632/oncotarget.17742
   PubMedGoogle Scholar
• Loong HH, Wong CK, Leung LK, et al. Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong. Cost Eff Resour Allocation. 2020;18(1):1–14. doi: 10.1186/s12962-020-0200-9
   PubMed Web of Science ®Google Scholar
• Miguel LS, Lopes FV, Pinheiro B, et al. Cost effectiveness of pembrolizumab for advanced melanoma treatment in Portugal. Value Health. 2017;20(8):1065–1073. doi: 10.1016/j.jval.2017.05.009
   PubMed Web of Science ®Google Scholar
• Wang J, Chmielowski B, Pellissier J, et al. Cost-effectiveness of Pembrolizumab versus Ipilimumab in Ipilimumab-naïve patients with advanced melanoma in the United States. JMCP. 2017;23(2):184–194. doi: 10.18553/jmcp.2017.23.2.184
   PubMed Web of Science ®Google Scholar
• Woods BS, Sideris E, Palmer S, et al. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23(12):1613–1621. doi: 10.1016/j.jval.2020.08.2094
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–1251. doi: 10.1016/S1470-2045(19)30388-2
   PubMed Web of Science ®Google Scholar
• Paly VF, Hikichi Y, Baker T, et al. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan. J Med Econ. 2020;23(12):1542–1552. doi: 10.1080/13696998.2020.1830781
   PubMed Web of Science ®Google Scholar
• Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5–21. doi: 10.1093/bmb/ldq033
   PubMed Web of Science ®Google Scholar
• The Central Bank of Islamic Republic of Iran (CBI) ER [2021 Feb 2]. Available from: https://fxmarketrate.cbi.ir/Default.aspx.
   Google Scholar
• Iran FaDAo. National Formulary of Iran 2020 [ Available from: http://irc.fda.gov.ir/NFI?Length=3.
   Google Scholar
• Summary of Product Characteristics . KEYTRUDA. First published July 30, 2015. Last updated March 29, 2016. Available from: http://www.ema.europa.eu/ema/. [Accessed Apr 1, 2016].
   Google Scholar
• Pembrolizumab (Keytruda), Merck & Co., Inc. USPI 09/2014, Drugs@FDA. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf.
   Google Scholar
• Hazarika M, Chuk MK, Theoret MR, et al. US FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on IpilimumabNivolumab for advanced melanoma. Clin Cancer Res. 2017;23(14):3484–3488. doi: 10.1158/1078-0432.CCR-16-0712
   PubMed Web of Science ®Google Scholar
• Modification of the Dosage Regimen for Nivolumab: U.S Food & Drug Administration. [ Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/modification-dosage-regimen-nivolumab.
   Google Scholar
• Hall E, Zhang J, Kim EJ, et al. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Med. 2020;9(6):2106–2112. doi: 10.1002/cam4.2888
   PubMed Web of Science ®Google Scholar
• Pembrolizumab (Keytruda), Merck & Co., Inc. USPI 01/2019, Drugs@FDA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s040lbl.pdf.
   Google Scholar
• Freshwater T, Kondic A, Ahamadi M, et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. Journal For ImmunoTherapy Of Cancer. 2017;5(1):1–9. doi: 10.1186/s40425-017-0242-5
   PubMedGoogle Scholar
• Peer CJ, Heiss BL, Goldstein DA, et al. Pharmacokinetic simulation analysis of less frequent nivolumab and pembrolizumab dosing: pharmacoeconomic rationale for dose deescalation. J Clin Pharmacol. 2022;62(4):532–540. doi: 10.1002/jcph.1984
   PubMed Web of Science ®Google Scholar
• Ogungbenro K, Patel A, Duncombe R, et al. Dose rationalization of pembrolizumab and nivolumab using pharmacokinetic modeling and simulation and cost analysis. Clin Pharmacol Ther. 2018;103(4):582–590. doi: 10.1002/cpt.875
   PubMed Web of Science ®Google Scholar
• Ipilimumab (YERVOY),Bristol-Myers Squibb company, USPI 06/2020, Drugs@FDA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s115lbl.pdf.
   Google Scholar
• Raedler LA. Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits. 2015;8(Spec Feature):180.
   PubMedGoogle Scholar
• Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384. doi: 10.1016/S1470-2045(15)70076-8
   PubMed Web of Science ®Google Scholar
• Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893–1901. doi: 10.1016/S0140-6736(12)60398-5
   PubMed Web of Science ®Google Scholar
• Statistical center of Iran. https://www.amar.org.ir/english/Statistics-by-Topic/National-accounts. 2020.
   Google Scholar
• W-X T, R-J S, Wang J, et al. Cost-effectiveness of Pembrolizumab versus Carboplatin and Paclitaxel in patients with unresectable or metastatic melanoma After first-line treatment in China. Value Health Reg Issues. 2022;27:99–107. doi: 10.1016/j.vhri.2021.04.007
   PubMedGoogle Scholar
• Gorry C, McCullagh L, Barry M. Economic evaluation of systemic treatments for advanced melanoma: a systematic review. Value Health. 2020;23(1):52–60. doi: 10.1016/j.jval.2019.07.003
   PubMed Web of Science ®Google Scholar
• Pike E, Torkilseng EB, Saeterdal I, et al. A health technology assessment of the new drugs for inoperable or metastatic malignant melanoma patients Internet. 2015.
   Google Scholar
• Giuliani J, Bonetti A. Immunotherapy in first-line for advanced non-small cell lung cancer: a cost-effective choice? Recenti Prog Med. 2019;110(3):138–143. doi: 10.1701/3132.31141
   PubMedGoogle Scholar
• Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535–e. doi: 10.1001/jamanetworkopen.2019.2535
   PubMed Web of Science ®Google Scholar
• Treish I, Al Rabayah A, Jaddoua S, et al. Impact of a new cost-effectiveness threshold implementation on cancer formulary decisions in Jordan. PharmacoEconomics-Open. 2022;6(2):137–145. doi: 10.1007/s41669-021-00293-4
   PubMed Web of Science ®Google Scholar
• Safari H, Poder TG, Afshari S, et al. Determination of a cost-effectiveness threshold for cancer interventions in Iran. Front Oncol. 2022;12:1039589. doi: 10.3389/fonc.2022.1039589
   PubMed Web of Science ®Google Scholar
• Wong EYT, Lim JFY, Toh HC. A review on paying for advanced cancer therapeutics: hard truths and realities in Asia. Chin Clin Oncol. 2023;12(4):40. doi: 10.21037/cco-23-37
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Atkins MB, Dicker AP, et al. The value of cancer immunotherapy summit at the 2016 Society for immunotherapy of cancer 31 st anniversary annual meeting. J Immunotherapy Cancer. 2017;5:38. doi: 10.1186/s40425-017-0241-6
   Google Scholar
• Organization WHO. Universal health coverage. Available online: https://www.who.int/healthsystems/universal_health_coverage/en/.
   Google Scholar
• Hosseinkhani N, Derakhshani A, Kooshkaki O, et al. Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies? Int J Mol Sci. 2020;21(21):8305. doi: 10.3390/ijms21218305
   PubMed Web of Science ®Google Scholar
• Bahmanyar M, Vakil MK, Al-Awsi GRL, et al. Anticancer traits of chimeric antigen receptors (CARs)-natural killer (NK) cells as novel approaches for melanoma treatment. BMC Cancer. 2022;22(1):1–9. doi: 10.1186/s12885-022-10320-0
   PubMed Web of Science ®Google Scholar
• Bahmanyar M, Vakil MK, Al-Awsi GRL, et al. Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review. Mol Biol Rep. 2022;49(11):10627–10633. doi: 10.1007/s11033-022-07633-5
   PubMed Web of Science ®Google Scholar
• Grosser R, Cherkassky L, Chintala N, et al. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471–482. doi: 10.1016/j.ccell.2019.09.006
   PubMed Web of Science ®Google Scholar
• Cherny N, Sullivan R, Torode J, et al. ESMO International Consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe. Ann Oncol. 2017;28(11):2633–2647. doi: 10.1093/annonc/mdx521
   PubMed Web of Science ®Google Scholar
• Leighl NB, Nirmalakumar S, Ezeife DA, et al. An arm and a leg: the rising cost of cancer drugs and impact on access. Am Soc Clin Oncol Educ Book. 2021;41(41):e1–e12. doi: 10.1200/EDBK_100028
   PubMedGoogle Scholar
• Organization WH Technical report: pricing of cancer medicines and its impacts: a comprehensive technical report for the world health assembly resolution 70.12: operative paragraph 2.9 on pricing approaches and their impacts on availability and affordability of medicines for the prevention and treatment of cancer. 2018.
   Google Scholar
• Oncology ASo C. American Society of clinical oncology position statement on addressing the affordability of cancer drugs. J Oncol Pract. 2018;14(3):187–192.
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Stemmer SM, Gordon N. The cost and value of cancer drugs–are new innovations outpacing our ability to pay? Isr J Health Policy Res. 2016;5(1):1–4. doi: 10.1186/s13584-016-0097-0
   PubMedGoogle Scholar
• Cheung W, Kornelsen E, Mittmann N, et al. The economic impact of the transition from branded to generic oncology drugs. Current Oncol. 2019;26(2):89–93. doi: 10.3747/co.26.4395
   PubMed Web of Science ®Google Scholar
• Bonetti A, Giuliani J. Implications of drugs with rebate in Europe. Lancet Regional Health–Europe. 2021;3:3. doi: 10.1016/j.lanepe.2021.100060
   Google Scholar
• Ferreira CG, Nicolini A, Dalurzo L, et al. The value of biomarkers in optimizing the use of Immuno-oncologic therapy. Curr Drug Targets. 2019;20(1):81–86. doi: 10.2174/1389450119666180911093143
   PubMed Web of Science ®Google Scholar
• Aguiar JP, Perry L, Penny-Dimri J, et al. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Ann Oncol. 2017;28(9):2256–2263. doi: 10.1093/annonc/mdx305
   PubMed Web of Science ®Google Scholar